Screener
Recursion Pharmaceuticals, Inc. RXRX PP&E (Net)
PP&E (Net) at other companies
Other financials
Where this comes from
Reported directly by Recursion Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.
The source filing: Recursion Pharmaceuticals, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 6:32 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001601830-26-000098
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Other current assets | 29,321 | 28,566 |
| Total current assets | 603,462 | 812,845 |
| Restricted cash, non-current | 5,752 | 6,033 |
| Property and equipment, net | 89,623 | 103,931 |
| Operating lease right-of-use assets | 40,271 | 45,339 |
| Financing lease right-of-use assets | 17,179 | 20,210 |
| Intangible assets, net | 282,888 | 309,903 |
| Goodwill | 160,350 | 162,158 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Recursion Pharmaceuticals, Inc.'s PP&E (net)?
- Recursion Pharmaceuticals, Inc. (RXRX) reported PP&E (net) of $89.62M in Q2 2026.
- How has Recursion Pharmaceuticals, Inc.'s PP&E (net) changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s PP&E (net) decreased by 25.3% year-over-year, from $120.04M to $89.62M.
- What is the long-term trend for Recursion Pharmaceuticals, Inc.'s PP&E (net)?
- Over 5 years (2020 to 2025), Recursion Pharmaceuticals, Inc.'s PP&E (net) has grown at a 32.0% compound annual growth rate (CAGR), from $25.97M to $103.93M.
- What does PP&E (net) mean?
- Total property, plant, and equipment minus accumulated depreciation — the net book value of all tangible long-lived assets.
Ask your AI about Recursion Pharmaceuticals, Inc.'s pp&e (net).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude